Cargando…

Sarcopenia and risk of infection in adult heart transplant recipients in Japan

AIMS: Heart transplantation (HT) is an effective therapeutic option for end‐stage heart failure. Infection is a major cause of morbidity and mortality after HT. Sarcopenia, defined as the loss of muscle mass and strength, is a common comorbidity in HT candidates with end‐stage heart failure. However...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsuji, Masaki, Kakuda, Nobutaka, Bujo, Chie, Ishida, Junichi, Amiya, Eisuke, Hatano, Masaru, Shimada, Asako, Imai, Hiroko, Shimada, Shogo, Kinoshita, Osamu, Yamauchi, Haruo, Ono, Minoru, Komuro, Issei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8934925/
https://www.ncbi.nlm.nih.gov/pubmed/35146960
http://dx.doi.org/10.1002/ehf2.13835
_version_ 1784671934295834624
author Tsuji, Masaki
Kakuda, Nobutaka
Bujo, Chie
Ishida, Junichi
Amiya, Eisuke
Hatano, Masaru
Shimada, Asako
Imai, Hiroko
Shimada, Shogo
Kinoshita, Osamu
Yamauchi, Haruo
Ono, Minoru
Komuro, Issei
author_facet Tsuji, Masaki
Kakuda, Nobutaka
Bujo, Chie
Ishida, Junichi
Amiya, Eisuke
Hatano, Masaru
Shimada, Asako
Imai, Hiroko
Shimada, Shogo
Kinoshita, Osamu
Yamauchi, Haruo
Ono, Minoru
Komuro, Issei
author_sort Tsuji, Masaki
collection PubMed
description AIMS: Heart transplantation (HT) is an effective therapeutic option for end‐stage heart failure. Infection is a major cause of morbidity and mortality after HT. Sarcopenia, defined as the loss of muscle mass and strength, is a common comorbidity in HT candidates with end‐stage heart failure. However, the effects of sarcopenia on the occurrence of post‐HT infections are not well understood. Therefore, we explored the association between the skeletal muscle mass and post‐transplant infections in adult HT recipients. METHODS AND RESULTS: We retrospectively examined the records of 135 patients who underwent HT between August 2007 and November 2019 at our institution. Pre‐transplant computed tomography was used to calculate the skeletal muscle index (SMI) at the level of the third lumbar vertebra. Muscle wasting was defined as the SMI of the lowest sex‐based tertiles. The primary endpoint was infections within 6 months of HT. The study included 109 patients (80 men, mean age: 41.6 ± 12.0 years): 37 patients in the muscle wasting group and 72 patients in the non‐muscle wasting group. The mean SMI values in the muscle wasting and non‐muscle wasting groups were 29.9 ± 4.8 cm(2)/m(2) and 40.7 ± 6.7 cm(2)/m(2), respectively. Prior to HT, 108 (99.1%) patients were on left ventricular assist device support, and during that support, the rate of late right heart failure was significantly higher in the muscle wasting group than non‐muscle wasting group (P = 0.012). Sixteen infections occurred within 6 months of HT. The most common infection sites included the respiratory tract (n = 5) and the upper gastrointestinal tract (n = 5), followed by the urinary tract (n = 4). Overall, 10 patients experienced infections in the muscle wasting group (27.0%) and 6 in the non‐muscle wasting group (8.3%) (P = 0.009). Two patients in the muscle wasting group required intensive care unit admission, compared to none in the non‐muscle wasting group. Low skeletal muscle mass was associated with infections in the univariate and multivariate logistic regression models (hazard ratio: 3.68, 95% confidence interval: 1.19–11.3; P = 0.023). However, the duration of all‐cause mortality within 3 years did not differ between the groups (P = 0.56). CONCLUSIONS: Low skeletal muscle mass is a predictor of post‐HT infections within 6 months of HT.
format Online
Article
Text
id pubmed-8934925
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-89349252022-03-24 Sarcopenia and risk of infection in adult heart transplant recipients in Japan Tsuji, Masaki Kakuda, Nobutaka Bujo, Chie Ishida, Junichi Amiya, Eisuke Hatano, Masaru Shimada, Asako Imai, Hiroko Shimada, Shogo Kinoshita, Osamu Yamauchi, Haruo Ono, Minoru Komuro, Issei ESC Heart Fail Original Articles AIMS: Heart transplantation (HT) is an effective therapeutic option for end‐stage heart failure. Infection is a major cause of morbidity and mortality after HT. Sarcopenia, defined as the loss of muscle mass and strength, is a common comorbidity in HT candidates with end‐stage heart failure. However, the effects of sarcopenia on the occurrence of post‐HT infections are not well understood. Therefore, we explored the association between the skeletal muscle mass and post‐transplant infections in adult HT recipients. METHODS AND RESULTS: We retrospectively examined the records of 135 patients who underwent HT between August 2007 and November 2019 at our institution. Pre‐transplant computed tomography was used to calculate the skeletal muscle index (SMI) at the level of the third lumbar vertebra. Muscle wasting was defined as the SMI of the lowest sex‐based tertiles. The primary endpoint was infections within 6 months of HT. The study included 109 patients (80 men, mean age: 41.6 ± 12.0 years): 37 patients in the muscle wasting group and 72 patients in the non‐muscle wasting group. The mean SMI values in the muscle wasting and non‐muscle wasting groups were 29.9 ± 4.8 cm(2)/m(2) and 40.7 ± 6.7 cm(2)/m(2), respectively. Prior to HT, 108 (99.1%) patients were on left ventricular assist device support, and during that support, the rate of late right heart failure was significantly higher in the muscle wasting group than non‐muscle wasting group (P = 0.012). Sixteen infections occurred within 6 months of HT. The most common infection sites included the respiratory tract (n = 5) and the upper gastrointestinal tract (n = 5), followed by the urinary tract (n = 4). Overall, 10 patients experienced infections in the muscle wasting group (27.0%) and 6 in the non‐muscle wasting group (8.3%) (P = 0.009). Two patients in the muscle wasting group required intensive care unit admission, compared to none in the non‐muscle wasting group. Low skeletal muscle mass was associated with infections in the univariate and multivariate logistic regression models (hazard ratio: 3.68, 95% confidence interval: 1.19–11.3; P = 0.023). However, the duration of all‐cause mortality within 3 years did not differ between the groups (P = 0.56). CONCLUSIONS: Low skeletal muscle mass is a predictor of post‐HT infections within 6 months of HT. John Wiley and Sons Inc. 2022-02-10 /pmc/articles/PMC8934925/ /pubmed/35146960 http://dx.doi.org/10.1002/ehf2.13835 Text en © 2022 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Tsuji, Masaki
Kakuda, Nobutaka
Bujo, Chie
Ishida, Junichi
Amiya, Eisuke
Hatano, Masaru
Shimada, Asako
Imai, Hiroko
Shimada, Shogo
Kinoshita, Osamu
Yamauchi, Haruo
Ono, Minoru
Komuro, Issei
Sarcopenia and risk of infection in adult heart transplant recipients in Japan
title Sarcopenia and risk of infection in adult heart transplant recipients in Japan
title_full Sarcopenia and risk of infection in adult heart transplant recipients in Japan
title_fullStr Sarcopenia and risk of infection in adult heart transplant recipients in Japan
title_full_unstemmed Sarcopenia and risk of infection in adult heart transplant recipients in Japan
title_short Sarcopenia and risk of infection in adult heart transplant recipients in Japan
title_sort sarcopenia and risk of infection in adult heart transplant recipients in japan
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8934925/
https://www.ncbi.nlm.nih.gov/pubmed/35146960
http://dx.doi.org/10.1002/ehf2.13835
work_keys_str_mv AT tsujimasaki sarcopeniaandriskofinfectioninadulthearttransplantrecipientsinjapan
AT kakudanobutaka sarcopeniaandriskofinfectioninadulthearttransplantrecipientsinjapan
AT bujochie sarcopeniaandriskofinfectioninadulthearttransplantrecipientsinjapan
AT ishidajunichi sarcopeniaandriskofinfectioninadulthearttransplantrecipientsinjapan
AT amiyaeisuke sarcopeniaandriskofinfectioninadulthearttransplantrecipientsinjapan
AT hatanomasaru sarcopeniaandriskofinfectioninadulthearttransplantrecipientsinjapan
AT shimadaasako sarcopeniaandriskofinfectioninadulthearttransplantrecipientsinjapan
AT imaihiroko sarcopeniaandriskofinfectioninadulthearttransplantrecipientsinjapan
AT shimadashogo sarcopeniaandriskofinfectioninadulthearttransplantrecipientsinjapan
AT kinoshitaosamu sarcopeniaandriskofinfectioninadulthearttransplantrecipientsinjapan
AT yamauchiharuo sarcopeniaandriskofinfectioninadulthearttransplantrecipientsinjapan
AT onominoru sarcopeniaandriskofinfectioninadulthearttransplantrecipientsinjapan
AT komuroissei sarcopeniaandriskofinfectioninadulthearttransplantrecipientsinjapan